

JUNE 2021



# Epidemiology data

# Infectious Diseases

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>Shingles / Herpes Zoster</b>	50+ population	132,406,309	147,989,589	552,294,333	62,718,587
	50+ population who could develop Shingles	12,075,123	13,496,279	50,367,855	5,719,778
<b>Respiratory syncytial virus (RSV)</b>	Older adults (65+)	73,137,000	80,653,293	N/A	36,872,819
	Older adults (60-64)	19,565,000	23,668,022	N/A	8,200,422
	Total 60+ population	92,702,000	104,321,315	N/A	45,073,241
	Maternal	4,195,000	1,529,000*	N/A	N/A
	Paediatric	4,195,000	3,059,000	N/A	947,000
<b>Meningitis ABCWY</b>	Adolescent cohort	5,992,000	3,431,929	N/A	N/A
	Infant cohort	N/A	3,073,340	3,844,500	N/A
<b>Uncomplicated Urinary Tract Infection (uUTI)</b>	Treatment episodes	15,015,090	15,200,806	36,646,455	2,917,115
	Episodes resistant to multiple classes or allergic to >= 3 antibiotic classes	3,087,120	2,164,554	4,431,253	423,762
	Episodes on novel antibiotic class	1,784,503	1,575,991	1,900,351	308,302
<b>Hepatitis B</b>	Diagnosed	611,098	966,205	6,556,247	636,812
	Recommended patients**	219,995	264,107	1,966,874	197,412

\* France and UK are not included in RSV-Maternal forecast due to underutilisation of maternal immunisation

\*\* Guideline recommended immune active patients



# HIV

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>HIV Treatment</b>	Prevalent	1,793,000	911,000	N/A	52,000
	Diagnosed	1,440,000	760,000	N/A	47,000
	Treated	1,146,000	678,000	N/A	44,000
	Naïve	352,000	194,000	N/A	10,000
	HTE	47,000	22,000	N/A	1,000
<b>HIV PrEP</b>	People who would benefit from PrEP (PWBP)	1,205,000	620,000	N/A	N/A

# Oncology

Infectious  
Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>Multiple myeloma</b>	1L drug treated patients	39,375	31,344	24,458	7,706
	2L drug treated patients	25,909	17,547	12,296	7,706
	3L drug treated patients	14,495	7,721	5,439	4,020
	4L+ drug treated patients	11,792	2,954	3,415	1,746
<b>Endometrial cancer (EC)</b>	Uterine cancer incidence	72,434	49,668	55,020	19,006
	EC incidence	66,639	45,695	50,618	17,486
	Advanced / recurrent drug treated patients	15,768	12,617	26,828	4,163
	1L A/R drug treated patients	9,771	8,422	10,836	2,746
	2L A/R drug treated patients	4,317	3,166	4,385	1,111
	dMMR MSI-H 2L EC patients	1,295	950	1,316	333
<b>Ovarian cancer</b>	Incidence	21,550	21,979	N/A	N/A
	1L drug-treated patients	19,591	19,981	N/A	N/A
	1L platinum-treated patients	16,884	18,582	N/A	N/A
	Patients eligible for maintenance	12,636	13,936	N/A	N/A
	Patients on maintenance	11,372	12,543	N/A	N/A

# Oncology

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>Breast cancer HR+HER2-</b>	Stage I-III incidence	223,429	201,015	N/A	N/A
	Stage I-III DTP	193,211	160,509	N/A	N/A
	PARP naïve	1,020	742	N/A	N/A
<b>Triple-negative breast cancer (TNBC)</b>	Stage I-III incidence	30,119	28,712	N/A	N/A
	Stage I-III DTP	24,921	26,115	N/A	N/A
	PARP naïve	7,931	7,578	N/A	N/A
<b>Squamous non-small cell lung cancer (NSCLC)</b>	Stage IV incidence	34,722	35,562	N/A	N/A
	1L drug-treated patients	30,208	30,228	N/A	N/A
	Patients on maintenance receiving PARP	4,652	4,655	N/A	N/A
<b>Non-Squamous non-small cell lung cancer (NSCLC)</b>	1L drug-treated patients	99,800	119,700	N/A	N/A

# Oncology

Infectious Diseases

HIV

**Oncology**

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>Non-squamous NSCLC</b>	Stage IV incidence	112,659	139,162	N/A	N/A
	1L drug-treated patients	98,013	118,288	N/A	N/A
	Patients on maintenance receiving PARP	10,977	13,248	N/A	N/A
<b>2L synovial sarcoma (SS)</b>	2L SS DTP	702	751	N/A	N/A
	Patients with access to treatment 1L (Geographical Impact)	562	601	N/A	N/A
	Biomarker Use	477	511	N/A	N/A
	2L MRCLS DTP	663	689	N/A	N/A
	Patients with access to treatment 1L (Geographical Impact)	530	551	N/A	N/A
	Biomarker Use	451	469	N/A	N/A

# Immunology / Respiratory

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity  
Driven



		US	EU5	China	Japan
<b>Severe Eosinophilic Asthma (SEA)</b>	Diagnosed prevalent patients	22,354,713	18,356,483	19,920,000	2,898,016
	Treated asthma patients (12+ age group)	10,888,523	12,854,663	11,000,000	2,134,495
	Patients on HD or MD ICS and eligible for biologic	2,950,000	1,288,616	994,958	243,545
	Patients with 2 or more exacerbations per year	805,011	289,098	994,958	243,545
	Patients eligible for biologics	483,006	173,458	596,975	107,160
<b>Hyper Eosinophilic Syndrome (HES)</b>	Diagnosed prevalent patients	5,310	3,570	5,940	N/A
	Treated patients	4,780	3,210	5,640	N/A
<b>Chronic Obstructive Pulmonary Disease (COPD)</b>	Diagnosed prevalent patients	14,798,643	13,545,769	26,832,970	1,902,351
	Treated patients	7,364,698	10,953,045	13,726,096	1,331,646
	Patients treated with inhaled triple therapy	2,651,291	2,893,858	7,901,188	506,582
	Patients with 2 or more exacerbations per year	1,282,883	753,319	2,939,242	188,448
	Patients eligible for biologics	389,387	101,766	661,329	42,401
<b>Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)</b>	CRS prevalent patients	9,388,050	9,542,070	73,424,125	1,080,997
	CRSwNP in CRS	2,347,010	2,385,520	10,279,378	229,815
	Treated patients	1,056,160	1,073,480	1,944,000	229,815
	1+ surgery patients	433,024	370,350	1,944,036	229,815
	NP recurrent patients	162,384	138,880	777,614	45,963



# Immunology / Respiratory

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity Driven



		US	EU5	China	Japan
<b>Eosinophilic Granulomatosis with Polyangiitis (EGPA)</b>	Diagnosed prevalent patients	7,440	4,380	5,730	15,540
	Treated patients	7,060	4,160	5,440	5,830
<b>Systemic Lupus Erythematosus (SLE)</b>	Prevalent patients	353,650	201,030	1,520,740	132,184
	Diagnosed patients	263,420	197,540	1,132,950	98,477
	ANA positive without CNS patients	243,000	182,000	753,000	93,000
	Patients eligible for biologics	160,020	44,917	336,825	58,386
<b>Rheumatoid Arthritis (RA)</b>	Prevalent patients	2,548,164	2,544,377	3,455,781	1,030,958
	Diagnosed patients	2,245,629	2,157,631	2,421,316	897,964
	Treated patients	2,133,347	1,567,055	2,045,793	588,200
	Patients with moderate-severe disease	1,397,342	996,647	1,329,765	385,271
	Eligible patients	1,048,007	740,890	825,661	254,959



# Opportunity Driven

Infectious Diseases

HIV

Oncology

Immunology/  
Respiratory

Opportunity Driven



		US	EU5	China	Japan
<b>Renal anaemia - non-dialysis</b>	Prevalent CKD (stage 3a-5)	24,801,656	20,581,121	N/A	N/A
	Diagnosed CKD	9,107,638	7,198,024	N/A	N/A
	Anaemia Hb<12	4,495,100	3,552,605	N/A	N/A
	Treatment eligible patients	1,904,202	1,039,922	N/A	N/A
<b>Renal anaemia - dialysis</b>	Diagnosed dialysis patients	769,929	446,283	N/A	N/A
<b>Renal anaemia - incident dialysis</b>	Diagnosed dialysis patients	181,329	105,105	N/A	N/A
<b>Primary Biliary Cholangitis (PBC)</b>	Diagnosed patients	109,544	N/A	238,156	35,738
	Patients with Cholestatic pruritus (CP)	51,865	N/A	108,197	21,648


# Definitions

<b>1L:</b>	first line
<b>2L:</b>	second line
<b>3L:</b>	third line
<b>4L:</b>	fourth line
<b>ANA:</b>	antinuclear antibodies
<b>CKD:</b>	chronic kidney disease
<b>CNS:</b>	central nervous system
<b>dMMR:</b>	mismatch repair-deficient
<b>DTP:</b>	drug-treated patients
<b>EU5:</b>	Germany, France, Italy, Spain, UK
<b>Hb:</b>	haemoglobin
<b>HD or MD ICS:</b>	high dose and medium dose inhaled cortico-steroid
<b>HER-:</b>	human epidermal growth factor receptor 2–negative
<b>HR+:</b>	hormone receptor–positive
<b>HTE:</b>	heavily treatment-experienced
<b>MRCLS:</b>	Mixoid Round Cell Liposarcoma
<b>MSI-H:</b>	microsatellite instability-high
<b>PARP:</b>	poly (ADP-ribose) polymerase
<b>PrEP:</b>	pre-exposure prophylaxis

**Sources:** Combination of scientific literature, external (e.g. Kantar), and internal quantitative market research

**Disclaimer:** Forecast data





**Contact:  
GSK Investor  
Relations Team**

+44 (0)20 8047 5000 or at  
[GSK.Investor-Relations@gsk.com](mailto:GSK.Investor-Relations@gsk.com)